More biotechs join S&P300 index
Friday, 05 September, 2003
Market analyst Standard and Poor's has added four more Australian biotechnology firms and a medical device company to its S&P300 index.
Circadian Technologies, Genetic Technologies, Metabolic Pharmaceuticals and Norwood Abbey, along with retractable syringe specialist Unitract, will join the index from September 19.
Tim Eisenhauer, S&P's head of index services, said companies were selected to join the index on the basis if the free float of their shares, on their market capitalisation, and their liquidity over a six-month period.
The last healthcare firm to join the 300 was artificial heart maker Ventracor.
The S&P300's healthcare board also includes Agenix, Cellestis, Chemeq, Cochlear, CSL, IDT, Novogen, Peptech, ResMed and Sirtex.
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
